Summary

KEY FINDINGS
The Europe botulinum toxin market is estimated to surge with a 10.00% CAGR during the assessment years 2023 to 2032. Market growth drivers in Europe for botulinum toxin procedures include rising consumer demand, an uncomplicated approval process, skilled professionals, and an increased geriatric population.
MARKET INSIGHTS
The Europe botulinum toxin market growth evaluation includes the analysis of Italy, Poland, Germany, Nordic Countries, the United Kingdom, Spain, France, and Rest of Europe. The market for botulinum toxin is growing in several European countries, with France and Italy being among the prominent markets. The increasing number of cosmetic practitioners and expansion of cosmetic clinics are expected to fuel the market growth in France.
Additionally, regulatory approvals and significant product developments are also expected to contribute to market growth in France. The use of botulinum toxin for treating spasticity in children with cerebral palsy is proving to be a safe and effective treatment option in France, although the cost of treatment for hospitals is relatively high.
On the other hand, Italy represents one of Europe’s largest markets for cosmetic procedures, attracting patients from neighboring countries such as Russia, Romania, and Switzerland. The quality of medical facilities and services, coupled with rising demand for cosmetic treatments and a growing geriatric population, is driving the demand for botulinum toxin in the country. The increasing demand for non-surgical cosmetic procedures is also driving market growth in Italy.

COMPETITIVE INSIGHTS
Some of the key market players entail Merz Pharma, Ipsen, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON BOTULINUM TOXIN MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. FAVORABLE REGULATORY APPROVALS ADD TO MARKET GROWTH
2.5.2. GROWING AWARENESS ABOUT ‘NOTOX’
2.5.3. INFLATING COSMETIC TOURISM ADDS TO THE DEMAND FOR BOTULINUM TOXIN
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGE IN DEMAND FOR AESTHETIC PROCEDURES
3.1.2. RISING GERIATRIC POPULATION
3.1.3. GROWING DEMAND FOR NON-INVASIVE COSMETIC PROCEDURES
3.2. KEY RESTRAINTS
3.2.1. CONCERNS REGARDING THE ADVERSE EFFECTS OF BOTULINUM TOXIN
3.2.2. LACK OF REIMBURSEMENT POLICIES SUPPORTING COSMETIC PROCEDURES
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR GERMANY
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
5. MARKET BY TYPE
5.1. TYPE A BOTULINUM TOXIN
5.2. TYPE B BOTULINUM TOXIN
6. MARKET BY USER DEMOGRAPHIC
6.1. WOMEN
6.2. MEN
7. MARKET BY APPLICATION
7.1. MEDICAL
7.1.1. CHRONIC MIGRAINE
7.1.2. MUSCLE SPASM
7.1.3. OVERACTIVE BLADDER
7.1.4. HYPERHIDROSIS
7.1.5. OTHER MEDICAL APPLICATIONS
7.2. AESTHETIC
7.2.1. CROW’S FEET
7.2.2. FOREHEAD LINES
7.2.3. FROWN LINES/GLABELLAR
7.2.4. SQUARE JAW/MASSETER
7.2.5. OTHER AESTHETIC APPLICATIONS
8. MARKET BY END-USER
8.1. SPECIALTY AND DERMATOLOGY CLINICS
8.2. HOSPITALS AND CLINICS
8.3. OTHER END-USERS
9. GEOGRAPHICAL ANALYSIS
9.1. EUROPE
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. EUROPE BOTULINUM TOXIN MARKET DRIVERS
9.1.3. EUROPE BOTULINUM TOXIN MARKET CHALLENGES
9.1.4. EUROPE BOTULINUM TOXIN MARKET REGULATORY FRAMEWORK
9.1.5. KEY PLAYERS IN EUROPE BOTULINUM TOXIN MARKET
9.1.6. COUNTRY ANALYSIS
9.1.6.1. UNITED KINGDOM
9.1.6.1.1. UNITED KINGDOM BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.2. GERMANY
9.1.6.2.1. GERMANY BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.3. FRANCE
9.1.6.3.1. FRANCE BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.4. ITALY
9.1.6.4.1. ITALY BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.5. SPAIN
9.1.6.5.1. SPAIN BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.6. NORDIC COUNTRIES
9.1.6.6.1. NORDIC COUNTRIES BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.7. POLAND
9.1.6.7.1. POLAND BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.8. REST OF EUROPE
9.1.6.8.1. REST OF EUROPE BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS
10.1.4. BUSINESS EXPANSIONS
10.2. COMPANY PROFILES
10.2.1. ABBVIE
10.2.1.1. COMPANY OVERVIEW
10.2.1.2. PRODUCT LIST
10.2.1.3. STRENGTHS & CHALLENGES
10.2.2. CANDELA MEDICAL
10.2.2.1. COMPANY OVERVIEW
10.2.2.2. PRODUCT LIST
10.2.2.3. STRENGTHS & CHALLENGES
10.2.3. DAEWOONG PHARMACEUTICAL CO LTD
10.2.3.1. COMPANY PROFILE
10.2.3.2. PRODUCT LIST
10.2.3.3. STRENGTHS & CHALLENGES
10.2.4. EVOLUS INC
10.2.4.1. COMPANY OVERVIEW
10.2.4.2. PRODUCT LIST
10.2.4.3. STRENGTHS & CHALLENGES
10.2.5. GALDERMA
10.2.5.1. COMPANY OVERVIEW
10.2.5.2. PRODUCT LIST
10.2.5.3. STRENGTHS & CHALLENGES
10.2.6. HUGEL INC
10.2.6.1. COMPANY OVERVIEW
10.2.6.2. PRODUCT LIST
10.2.6.3. STRENGTHS & CHALLENGES
10.2.7. IPSEN
10.2.7.1. COMPANY OVERVIEW
10.2.7.2. PRODUCTS / SERVICES LIST
10.2.7.3. STRENGTHS & CHALLENGES
10.2.8. LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS CO LTD
10.2.8.1. COMPANY OVERVIEW
10.2.8.2. PRODUCT LIST
10.2.8.3. STRENGTHS & CHALLENGES
10.2.9. MEDYTOX INC
10.2.9.1. COMPANY OVERVIEW
10.2.9.2. PRODUCT LIST
10.2.9.3. STRENGTHS & CHALLENGES
10.2.10. MERZ PHARMA
10.2.10.1. COMPANY OVERVIEW
10.2.10.2. PRODUCT LIST
10.2.10.3. STRENGTHS & CHALLENGES
10.2.11. REVANCE THERAPEUTICS INC
10.2.11.1. COMPANY OVERVIEW
10.2.11.2. PRODUCT LIST
10.2.12. US WORLDMEDS LLC
10.2.12.1. COMPANY OVERVIEW
10.2.12.2. PRODUCT LIST